Manufacturer of Controlled Substances; Notice of Application; Cedarburg Pharmaceuticals, Inc., 67676 [2012-27572]
Download as PDF
<![CDATA[
67676
Federal Register / Vol. 77, No. 219 / Tuesday, November 13, 2012 / Notices
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
SA INTL GMBH C/O., Sigma Aldrich
Co. LLC., to import the basic classes of
controlled substances is consistent with
the public interest, and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated SA INTL GMBH C/O.,
Sigma Aldrich Co. LLC., to ensure that
the company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic classes of
controlled substances listed.
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Cedarburg Pharmaceuticals, Inc.
Schedule
srobinson on DSK4SPTVN1PROD with
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Regarding the drug code (8333), the
company plans to use this controlled
substance to manufacture another
controlled substance.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
VerDate Mar<15>2010
17:08 Nov 09, 2012
Jkt 229001
[FR Doc. 2012–27572 Filed 11–9–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 14, 2013.
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–27565 Filed 11–9–12; 8:45 am]
Manufacturer of Controlled
Substances; Notice of Application;
Johnson Matthey Inc.
Drug
Pursuant to § 1301.33(a), of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 21,
2012, Cedarburg Pharmaceuticals, Inc.,
870 Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
4-Anilino-N-phenethyl-4-piperidine
(8333).
Fentanyl (9801) ............................
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 10,
2012, Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
[FR Doc. 2012–27571 Filed 11–9–12; 8:45 am]
Drug
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 14, 2013.
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Propiram (9649) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Wildlife Laboratories, Inc.
By Notice dated April 17, 2012, and
published in the Federal Register on
July 31, 2012, 77 FR 45378, Wildlife
Laboratories, Inc., 1230 W. Ash Street,
Suite D, Windsor, Colorado 80550,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Carfentanil (9743), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the above listed controlled substance for
sale to veterinary pharmacies, zoos, and
for other animal and wildlife
applications.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Wildlife Laboratories, Inc., to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Wildlife Laboratories, Inc.,
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
E:\FR\FM\13NON1.SGM
13NON1
]]>Agencies
[Federal Register Volume 77, Number 219 (Tuesday, November 13, 2012)]
[Notices]
[Page 67676]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27572]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Cedarburg Pharmaceuticals, Inc.
Pursuant to Sec. 1301.33(a), of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on September 21, 2012, Cedarburg
Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024,
made application by renewal to the Drug Enforcement Administration
(DEA) to be registered as a bulk manufacturer of the following basic
classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
4-Anilino-N-phenethyl-4-piperidine (8333).. II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers. Regarding the drug code
(8333), the company plans to use this controlled substance to
manufacture another controlled substance.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than January 14, 2013.
Dated: November 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-27572 Filed 11-9-12; 8:45 am]
BILLING CODE 4410-09-P
